Restricted accessResearch articleFirst published online 2022-6
Reply to Kawasaki et al Regarding “Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast”
SeijnhaeveEGalantCVan BockstalMR. Nuclear insulinoma-associated protein 1 expression as a marker of neuroendocrine differentiation in neoplasms of the breast. Int J Surg Pathol2021;29(5):496‐502.
2.
KawasakiTKairaK. Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective. Virchows Arch2021;479(1):191‐194.
3.
WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. (: International Agency for Research on Cancer, 2019.
4.
AllisonKHHammondMEHDowsettM, et al. Estrogen and progesterone receptor testing in breast cancer: american society of clinical oncology/college of American pathologists guideline update. Arch Pathol Lab Med2020; 144(5): 545‐563.
5.
MetovicJCastellanoIMarinelliE, et al. INSM1 Expression in breast neoplasms with neuroedocrine features. Endocr Pathol2021; 32(4): 452‐460.
6.
Turkevi-NagySBáthoriÁBöczJ, et al. Syntaxin-1 and insulinoma-associated protein 1 expression in breast neoplasms with neuroendocrine features. Pathol Oncol Res2021;27: 1610039.
7.
RazviHTsangJYPoonIK, et al. INSM1 Is a novel prognostic neuroendocrine marker for luminal B breast cancer. Pathology2021; 53(2): 170‐178.
8.
BoginaGMunariEBrunelliM, et al. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology2016;68(3):422‐432.
9.
ParejaFVahdatiniaMMarchioC, et al. Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. J Clin Pathol2022;75(1):10‐17.
10.
UccellaSFinziGSessaFLa RosaS. On the endless dilemma of neuroendocrine neoplasms of the breast: a journey through concepts and entities. Endocr Pathol2020; 31(4): 321‐329.
